Season 4 of Superbugs and You is here! Episode 16: One Health is a concept that recognizes this interconnection and emphasizes the need for collaborative approaches to solving the issue of antimicrobial resistance at all levels -  humans, animals, and the environment is undeniable. Guests on this episode include Lance Price, (George Washington University), Francisco Diez-Gonzales (University of Georgia), and Paul Plummer (Iowa State University).  

Season 4 of Superbugs and You is here! Episode 15: Antimicrobials are the cornerstone of modern medicine, and this is especially true for patients with cystic fibrosis. People with CF rely on antibiotics for recurring and persistent infections, and with regular use, antibiotics become less and less effective in fighting these infections. Guests include Ella Balasa, (Patient Advocate), Helen Boucher, MD (Tufts Medicine), and Mary Booth Dwight (Cystic Fibrosis Foundation).  

Season 4 of Superbugs and You is here! Episode 14: This year, Italy leads the Presidency of the G7. The group is united by common values in addressing global challenges, including antimicrobial resistance. This episode features Italian leaders driving transformational policy to battle AMR. Guests include Francesca Chiara, (CIDRAP ASP), Mariano Votta (Active Citizenship Network-Cittadinanzattiva), Damiano De Felice (CARB-X), and Massimo Sartelli (Global Alliance for Infections in Surgery).  

Health officials around the world are sounding the alarm on a highly infectious bacteria causing extensively drug-resistant infections. Shigella, which causes the infection known as shigellosis, is a genus of bacteria that results in gastrointestinal distress that ranges from uncomfortable to deadly, in adults and children. Global surveillance efforts on Shigella have identified outbreaks of strains that are extensively drug-resistant across the UK, US, and parts of Europe. How is the world...

Superbugs & You Season 3 is here! The latest episode of the podcast covers the impact of typhoid vaccination on AMR and the successes and challenges to deploying effective programs globally. Guests include Farah Naz Qamar, Kathy Neuzil, Denise Garrett, and Calman MacLennan.

Superbugs & You Season 3 is here! The latest episode on treatment-resistant neonatal sepsis highlights how the infection prevention strategies, diagnostics, and therapeutics can make a difference in the smallest of patients. Despite great improvements in mortality for children under 5, sepsis remains a leading cause of death in young children. Guests include Kamala Thiagarajan, Phoebe Williams, and Seamus O'Brien.

Around the world, the multidrug resistant and pan-resistantfungus Candida auris has caused outbreaks in healthcare systems. While it is now highlighted by CDC as an urgent threat, only six years ago there were no reports of resistant C. auris strains that were able to spread easily between patients. These infections are challenging to treat a with 5% — 10% of colonized patients going on to develop invasive infections. This episode will cover how these outbreaks have impacted patients,...

Defined as ​an “urgent” AMR threat by the US CDC, resistant Acinetobacter baumanii cause deadly infections and are difficult to remove from the environment. Acinetobacter is resistant to many antibiotics and is a frequent cause of hospital acquired infections. In the 2022 Lancet publication on drug-resistant infections (GRAM report), it was identified as the leading pathogen causing mortality in Southeast Asia. This episode will cover how infections caused by resistant Acinetobacter impact...

Join us for a sneak peak of Season 3 of Superbugs and You by listening to a portion of our interview with Dr. Tom Chiller, Chief of the Mycotic Diseases Branch at the Centers for Disease Control and Prevention, discussing Candida auris.

For Fungal Disease Awareness Week, we’re giving you a sneak peak at the upcoming third season of “Superbugs and You: True Stories from Scientists and Patients Around the World”. In this episode, we share a portion of our interview with Dr. Tom Chiller, Chief of the Mycotic Diseases Branch at the Centers for Disease Control and Prevention, discussing Candida auris. This podcast series, "Superbugs and You", explores the threat of antimicrobial resistance, which occurs when bacteria, viruses,...

Neisseria gonorrhoeae is the second most common bacterial sexually transmitted infection in the world, and it has become a superbug. It has developed resistance to every antibiotic currently approved for treatment, and multidrug-resistant strains have been identified globally. Hear from clinicians advocating for their patients, a global leader, and a leading expert in drug development on actions needed to combat resistant gonorrhea.

Neisseria gonorrhoeae is the second most common bacterial sexually transmitted infection in the world, and it has become a superbug. It has developed resistance to every antibiotic currently approved for treatment, and multidrug-resistant strains have been identified globally. Hear from clinicians advocating for their patients, a global leader, and a leading expert in drug development on actions needed to combat resistant gonorrhea.

In this episode, we will explore the ways that antimicrobial resistance impacts treatment for some of the most vulnerable patients, such as those undergoing cancer treatment or receiving bone marrow transplants. A recent survey of oncologists showed that 95% of them worry about the impact of superbugs on the future of cancer treatments, and one in five patients receiving chemotherapy will have a bacterial infection. In this episode, you will hear directly from a patient who had a bacterial...

In this episode, we will explore the ways that antimicrobial resistance impacts treatment for some of the most vulnerable patients, such as those undergoing cancer treatment or receiving bone marrow transplants. A recent survey of oncologists showed that 95% of them worry about the impact of superbugs on the future of cancer treatments, and one in five patients receiving chemotherapy will have a bacterial infection. In this episode, you will hear directly from a patient who had a bacterial...

Clostridioides difficile (also known as C. diff or CDI) can cause deadly diarrhea. It is the most common healthcare-associated infection in the United States and rates of infections are rising globally. In this episode, we hear how a young Mom was impacted by the disease, how leading healthcare organizations are driving best practice guidelines, and how the US CDC is tracking this superbug.

Methicillin-resistant S. aureus (MRSA) is found in the community and in healthcare systems. According to the WHO, hospitalized patients with MRSA infections are 64% more likely to die than people with drug-sensitive infections. It can be difficult to treat. In this episode, hear from a patient who battled an infection for years, a infectious disease clinician who shares his daily challenges, and a researcher who using an unique approach to find the next antibiotic.

Methicillin-resistant S. aureus (MRSA) is found in the community and in healthcare systems. According to the WHO, hospitalized patients with MRSA infections are 64% more likely to die than people with drug-sensitive infections. It can be difficult to treat. In this episode, hear from a patient who battled an infection for years, a infectious disease clinician who shares his daily challenges, and a researcher who using an unique approach to find the next antibiotic.

In Season 2 of Superbugs and You, we continue to focus on the threat of antimicrobial resistance, which occurs when bacteria, viruses, fungi and parasites change over time and no longer respond to antibiotics and other medicines. In other words, they become “Superbugs”. This season, we will focus on Methicillin-resistant Staphylococcus aureus, Clostridioides difficile infections, resistant Neisseria gonorrhoeae, and the impact of antimicrobial resistance on modern medicine. Each episode...

In this final episode of Season 1, we discuss how the COVID-19 pandemic has impacted strategies to address antimicrobial resistance. Our guests will describe the patient experience of surviving COVID, the role of antimicrobial stewardship in managing COVID patients, and how the COVID-19 pandemic potentiates AMR and emerging approaches to the surveillance, treatment and prevention of AMR.

In this final episode of Season 1, we discuss how the COVID-19 pandemic has impacted strategies to address antimicrobial resistance. Our guests will describe the patient experience of surviving COVID, the role of antimicrobial stewardship in managing COVID patients, and how the COVID-19 pandemic potentiates AMR and emerging approaches to the surveillance, treatment and prevention of AMR.

In this episode, we discuss the global issue of multidrug-resistant tuberculosis or TB. Our guests in this episode will describe living with TB, and the experience of managing these difficult-to-treat infections. They will also examine the role that social structures, local governance, accessible and affordable treatments, and patient advocacy play in tuberculosis transmission and management.

In this episode, we discuss the global issue of multidrug-resistant tuberculosis or TB. Our guests in this episode will describe living with TB, and the experience of managing these difficult-to-treat infections. They will also examine the role that social structures, local governance, accessible and affordable treatments, and patient advocacy play in tuberculosis transmission and management.

In this episode, we discuss sepsis and the challenge of an infection caused by a drug-resistant microorganism. Our guests describe the long-term patient experience of surviving and living with a sepsis diagnosis, as well as the current diagnosis and treatment options for sepsis. Finally, we discuss global approaches for new treatments, and the need for advocacy and awareness. 

In this episode, we discuss sepsis and the challenge of an infection caused by a drug-resistant microorganism. Our guests describe the long-term patient experience of surviving and living with a sepsis diagnosis, as well as the current diagnosis and treatment options for sepsis. Finally, we discuss global approaches for new treatments, and the need for advocacy and awareness.